Business
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
– Other Studies Highlight Impact of Linaclotide in Adult and Pediatric Populations, Highlight Disease Burden – BOSTON--(BUSINESS WIRE)-- Ironwood
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Other Studies Highlight Impact of Linaclotide in Adult and Pediatric Populations, Highlight Disease Burden –\n\n BOSTON--(BUSINESS WIRE)--\nIronwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week® (DDW) meeting that suggest colonic IW-3300 has the potential to help manage abdominopelvic visceral pain in patients with disorders of gut-brain interaction (DGBI) and related visceral pain disorders. The oral presentation, titled Colon-Targeted Delivery Of Guanylate Cyclase-C Agonist IW-3300 Relieves Comorbid Chronic Pelvic And Somatic Pain In A Rat Model Of Early Life Stress-Induced Colonic Hypersensitivity (presentation number 240), provided evidence that delivery of IW-3300 to the colorectal region inhibits overlapping chronic pelvic pain in an established preclinical model of early-life stress induced colonic hypersensitivity.\n\nIronwood is currently developing IW-3300, a guanylate cyclase-c (GC-C) agonist, for the potential treatment of visceral pain conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis. The compound is currently in Phase I trials that will lay the foundation to potentially clinically test the cross-talk hypothesis in humans for the first time. Cross-talk is a biological phenomenon where sensations of injury originating in one abdominal or visceral organ can result in altered sensation in a nearby organ because of overlapping nerve pathways.\n\n“Visceral pain is the most common type of pain associated with disease, and yet treating patients with this type of pain remains a significant challenge,” said Beverley Greenwood-Van Meerweld, Ph.D., George Lynn Cross Research Professor Emeritus, President’s Associates Presidential Professor, University of Oklahoma Health Sciences Center. “These results are exciting because they show the potential of IW-3300 to relieve visceral pain via a neuronal cross-talk mechanism mediated by the GC-C pathway. I look forward to future results from clinical trials of the compound.”\n\nIronwood Pharmaceuticals and its collaborators also presented results from a post-hoc analysis of linaclotide studies focused on further understanding its treatment effect on abdominal symptoms in patients with Irritable Bowel Syndrome with Constipation (IBS-C). Other studies prese...